L-serine

Generic name
L-serine
Brand name
ATC Code
V06DD
Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Phosphoglycerate dehydrogenase deficiency, serine biosynthesis disorders
  • Oral
    • 0 years up to 18 years
      • 400 - 650 mg/kg/day in 3 doses. Max: 650 mg/kg/day.

      • The dosage is determined for the individual depending on the levels in the serum and CSF.

        Treatment by a paediatric specialist (metabolic disorders) who has experience using L-serine for this indication.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

GENERAL NUTRIENTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

OTHER NUTRIENTS
V06DD

Reference

  1. Blau, Hoffmann, Leonard and Clarke, Physicians guide to the treatment and follow-up of metabolic diseases., Springer, 2006

Changes

Therapeutic Drug Monitoring


Overdose